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Abstract: 
The identification and development of novel nontoxic phytochemicals that target androgen and androgen 
receptor (AR) signaling remains a priority for prostate cancer (PCA) control. In the present study, we assessed 
the antiandrogenic efficacy of isosilybin B employing human PCA LNCaP (mutated AR), 22Rv1 (mutated AR) 
and LAPC4 (wild-type AR) cells. Isosilybin B (10–90 µM) treatment decreased the AR and prostate specific 
antigen (PSA) levels in LNCaP, 22Rv1 and LAPC4 cells, but not in non-neoplastic human prostate epithelial 
PWR-1E cells. Isosilybin B treatment also inhibited synthetic androgen R1881-induced nuclear localization of 
AR, PSA expression and cell growth, and caused G1 arrest. In mechanistic studies identifying AR degradation, 
isosilybin B caused increased phosphorylation of Akt (Ser-473 and Thr-308) and Mdm2 (Ser-166), which was 
linked with AR degradation as pretreatment with PI3K inhibitor (LY294002)-restored AR level. Further, over-
expression of kinase-dead Akt largely reversed isosilybin B mediated-AR degradation suggesting a critical role 
of Akt in AR degradation. Antibody pull-down results also indicated that isosilybin B treatment enhances the 
formation of complex between Akt, Mdm2 and AR, which promotes phosphorylation-dependent AR ubiquiti-
nation and its degradation by proteasome. Together, present findings identify a novel mechanism for isosilybin 
B-mediated anticancer effects in human PCA cells.  




Androgen and androgen receptor (AR) mediated signaling plays a critical role in the development and 
progression of prostate cancer (PCA), which is the leading cause of cancer-related deaths in American men 
(Jemal et al., 2007). For last few decades, surgical or chemical ablation of androgens has been the frontline 
therapy for treating patients with locally advanced or metastatic PCA (Grossmann et al., 2001; Chen et al., 
2004). Although most patients initially respond to these treatments, the disease eventually progresses to hor-
mone-refractory state, which is caused mainly by AR overexpression, mutations or post-translational activation 
of the receptor or its coactivators (Grossmann et al., 2001; Chen et al., 2004; Sharifi and Farrar, 2006). These 
changes allow AR to become activated by low levels of adrenal androgens, other steroids and even 
antiandrogens or by ligand-independent mechanisms (Sharifi and Farrar, 2006). Therefore, aiming only at 
reducing the circulating levels of androgens or use of antiandrogens could be a major reason for an overall 
failure of endocrine therapy. Hence, ablation of AR from PCA cells using nontoxic phytochemicals could be an 
attractive therapeutic strategy for this deadly malignancy. 
 
Silymarin is a crude extract of flavonolignans obtained from milk thistle (Silybum marianum (L.) Gaertn.) 
seeds, and is widely known for its hepato- protective and cancer chemopreventive action (Wellington and 
Jarvis, 2001; Singh and Agarwal, 2002, 2006; Deep et al., 2006). Recently, we have isolated and purified from 
silymarin seven distinct flavonolignans namely silybin A, silybin B, isosilybin A, isosilybin B, silydianin, 
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silychristin, isosilychristin and one flavonoid taxifolin (Kim et al., 2003); and assessed their biological effects 
on many antiproliferative end points in human PCA cell lines (Davis-Searles et al., 2005). Isosilybin B ranked 
the most potent flavonolignan for nearly all end points including inhibition of prostate-specific antigen (PSA) 
secretion (Davis-Searles et al., 2005), which is used as a clinical tool in screening, diagnosis and treatment 
decisions for human PCA (Nelson et al., 2003). Here we conducted detailed mechanistic studies with isosilybin 
B focusing on AR by employing androgen-dependent LNCaP cells with single AR mutation (T877A), LAPC4 
cells with wild-type AR and androgen-independent 22Rv1 cells with mutated AR (H874Y), though all the three 
cell lines have functional AR (Nagabhushan et al., 1996; Klein et al., 1997; Mendoza et al., 2002; Bernard et 
al., 2003). 
 
Androgen receptor is a phosphoprotein and its activity is regulated through phosphorylation by many kinases. 
Various studies have shown the role of glycogen synthase kinase 30 (GSK30), stress kinase, mammalian target 
of rapamycin (mTOR) kinase and cyclin-dependent kinase 1 in regulating phosphorylation, stability and 
localization of AR (Wang et al., 2004; Cinar et al., 2005; Chen et al., 2006; Gioeli et al., 2006). Further, there 
are numerous studies suggesting the importance of Akt/PKB (a serine/threonine kinase) activation in AR 
degradation (Lin et al., 2001, 2002; Liao et al., 2005) as well as AR activation (Miyamoto et al., 2005; Reddy et 
al., 2006); though the interaction of Akt with AR largely remains unclear. Accordingly, we also examined the 
effect of isosilybin B on Akt phosphorylation and its possible role in AR degradation. 
 
Results 
Effect of isosilybin B and its other isomers on PSA and AR levels  
Recently we showed the effect of isosilybin B and its other isomers namely silybin A, silybin B and isosilybin 
A (Figure 1 a) on secreted PSA levels in LNCaP cells after 72h treatment (Davis-Searles et al., 2005). Here, 
first we examined a comparative effect of these diastereoisomers, following 24h of their treatment, on both 
secreted and intracellular PSA levels in PCA LNCaP, 22Rv1 and LAPC4 cells. All four pure compounds (at 
90µM) decreased PSA levels (secreted as well as intracellular) in LNCaP (Figure 1b), 22Rv1 (Figure 1c) and 
LAPC4 (Figure 1 d) cells, though isosilybin B was far more potent compared to silybin A, silybin B and 
isosilybin A (Figures 1b–d). The comparative superior efficacy of isosilybin B on secreted PSA inhibition in 
LNCaP, 22Rv1 and LAPC4 cells was also confirmed by ELISA assay (Figure 1e). Since AR (110 kDa in 
LNCaP cells and 114 kDa in 22Rv1 cells) is known to regulate the expression of androgen response element 
(ARE) containing genes including PSA (Miyamoto et al., 2005), next we examined a comparative effect of 
these compounds on AR levels. In all the three cell lines, isosilybin B strongly decreased the AR protein levels, 
while the effect of silybin A, silybin B and isosilybin A on AR levels was either marginal or was relatively 
lesser (Figures 1b–d). Together, these results suggest that among all the four isomers, isosilybin B is most 
effective in decreasing PSA and AR protein levels. Accordingly, we selectively focused our efforts to conduct 
detailed studies only with isosilybin B. 
 
In LNCaP cells, isosilybin B (10–90 µM) decreased AR and PSA (both secreted and cellular) levels after 24, 48 
and 72h of treatment (Figure 2a). Similarly, isosilybin B treatment (60 and 90 µM) decreased AR and PSA 
levels in 22Rv1 and LAPC4 cells after 24 and 48h of treatment (Figures 2b and c). Importantly, isosilybin B did 
not alter AR and cellular PSA levels in non-neoplastic human prostate epithelial PWR-1E cells under identical 
treatment conditions (Figure 2d), suggesting a selectivity in its response only toward human PCA cells. The 
secreted level of PSA was not detectable in PWR-1E cells (data not shown). 
 
Isosilybin B decreases AR protein levels in both nuclear and cytoplasmic fractions 
Since nuclear localization of AR is essential for its transcriptional activity (Miyamoto et al., 2005), we next 
evaluated the effect of isosilybin B on AR localization where its treatment for 6h slightly decreased the 
cytoplasmic and nuclear AR level (Figure 3a). Longer treatments (24–72h), however, strongly decreased both 
cytoplasmic and nuclear AR levels in a time-dependent manner (Figure 3a). We also observed a dose-dependent 
decrease in AR levels in both cytoplasmic and nuclear fractions after 72h of isosilybin B treatment (Figure 3b). 
A similar decrease in both cytoplasmic and nuclear AR levels was also observed in 22Rv1 cells following 24 
and 48h of isosilybin B treatment (Figure 3c). Purity of nuclear and cytoplasmic fractions was confirmed by 
reprobing the membranes with histone H1 and tubulin, detectable only in nuclear and cytoplasmic fractions, 
respectively. 
PSA suppression by isosilybin B persists after its removal To assess whether the effect of isosilybin B on AR 
signaling is long lasting or reversible, LNCaP and 22Rv1 cells were treated with isosilybin B (90 µM) for 24h 
and then conditioned medium was carefully removed, and cells were washed twice with fresh medium to 
remove both residual isosilybin B and secreted PSA. Fresh medium was then added and secreted PSA levels 
were measured as a function of time. As shown in Figure 3d, only 24h of isosilybin B treatment followed by 
wash-out study till 72 and 48 h in LNCaP and 22Rv1 cells, respectively, showed only a marginal reversal in the 
observed decrease in secreted PSA levels (Figure 3d). Similarly, cell number (LNCaP and 22Rv1) also 
remained significantly decreased even after isosilybin B withdrawal (Figure 3e). 
 
Isosilybin B inhibits R1881-mediated nuclear localization/ expression of AR 
Next we examined the effect of isosilybin B on synthetic androgen R1881 (methyltrienolone)-mediated nuclear 
localization/expression of AR. LNCaP cells grown in charcoal/dextran-treated fetal bovine serum (cFBS) were 
pretreated with 90µM isosilybin B for 2h and then stimulated with 1 nM R1881 for 150min and 
nuclear/cytoplasmic fractions were subsequently prepared. We observed an increased nuclear localization of 
AR with R1881, which was strongly reduced by isosilybin B (Figure 4a). We also validated these results 
employing confocal microscopy under identical treatment conditions. Here, fluorescein isothyocyanate (FITC) 
staining (for AR) was predominantly cytoplasmic in cells grown in cFBS, which becomes strongly nuclear in 
presence of R1881, and isosilybin B pretreatment followed by R1881 showed diffused FITC staining across 
both cytoplasm and nucleus (Figure 4a). In another experiment, 90 µM isosilybin B was incubated with 1 nM 
R1881 
 
in media for 10 min and then cells were treated with this mixture for 150 min, and both nuclear and cytoplasmic 
fractions were examined for AR levels. Under these conditions also, isosilybin B attenuated R1881-induced 
nuclear localization of AR (data not shown). In a related experiment, LNCaP cells were grown under 10% cFBS 
plus 1 nM R1881 for 4 days and isosilybin B was added for 24h. Here too, isosilybin B decreased R1881-
mediated increase in AR level especially in nuclear fraction, as well as R1881-stimulated PSA 
 
levels (Figure 4b) illustrating that isosilybin B inhibits androgen-induced AR signaling. 
 
Isosilybin B inhibits R1881-stimulated growth of LNCaP cells 
We also assessed the effect of isosilybin B treatment on androgen-stimulated growth of LNCaP cells, where 
compared to 10% FBS, cells grown in 10% cFBS showed a marked reduction in growth (Figure 4c). This was 
expected because cFBS is devoid of hormones and other growth promoting agents. Cells grown in 10% cFBS + 
0.1 nM R1881 showed greater cell growth compared to cultures grown in cFBS (Figure 4c). Isosilybin B 
treatment (90µM) for 24h inhibited the majority of R1881-stimulated cell growth (Figure 4c). 
 
Isosilybin B induces G1 arrest in serum- and androgen-stimulated LNCaP cells 
The treatment of LNCaP cells grown in 10% FBS with isosilybin B resulted in significant G1 arrest (Figure 4d). 




androgen in cFBS was a major factor for observed G1 arrest in 10% cFBS grown cells and that whether 
isosilybin B inhibits R1881-stimulated cell cycle progression. Compared with 10% cFBS alone, cells grown in 
10% cFBS +0.1 nM R1881 showed a release from G1 arrest, but treatment of R1881-stimulated cells with 
isosilybin B restored cell cycle arrest (Figure 4d). These data suggest that growth inhibitory effects of isosilybin 
B could be due to its activity toward androgen-AR signaling. 
 
Isosilybin B causes a decrease in AR half-life 
We next focused our efforts on identifying whether post-translational modifications play a role in isosilybin B-
mediated AR decrease. To address this issue, protein synthesis inhibitor cycloheximide (CHX) was added in 
LNCaP cells with or without isosilybin B (90 gM), and as a function of time cells were harvested and AR 
protein level measured by western blotting. In isosilybin B-treated LNCaP cells, the half-life of AR protein was 
reduced to 6.8 h from 13.8 h in control cells (Figure 5a), suggesting that the observed decrease in AR protein 
level by isosilybin B could be due to post-translational degradation. Based on this observation, next we focused 
our efforts on AR degradation by post-translational mechanisms. 
 
Isosilybin B increases the phosphorylation of Akt 
Akt (60 kDa) is one such kinase whose role has been described in the phosphorylation and degradation of AR 
(Lin et al., 2001, 2002). Therefore, we next examined the effect of isosilybin B treatment on Akt phospho-
rylation. Isosilybin B treatment of LNCaP cells increased phosphorylation levels of Akt at Ser-473 and Thr-308 
sites (Figure 5b) without any changes in total Akt after 24h; however, at later time points (48 and 72h) and 
higher doses decreased the total Akt levels. So in further studies to understand the effect of isosilybin B 
treatment on Akt–AR interaction, we focused, on 24h or earlier time point. Similar to results in LNCaP cells 
isosilybin B treatment also caused a significant increase in Akt phosphorylation at Ser-473 site in 22Rv1 cells 
(Figure 5c). Together, these similar results in two different cell lines provided us further impetus to investigate 
the role of Akt in isosilybin B-mediated AR degradation. 
 
Role of Akt in isosilybin B-mediated AR degradation To dissect the role of Akt activation in isosilybin B-
mediated AR degradation, we pretreated LNCaP cells with 20 gM dose of PI3K inhibitor (LY294002), which 
resulted in inhibition of Akt phosphorylation (Figure 6a). When isosilybin B (90 gM) was added after PI3K 
inhibitor, a decrease in AR level was no longer evidenced (Figure 6a) and PI3K inhibitor also largely reversed 
isosilybin B-mediated decrease in PSA level (Figure 6a). Together, these results identified the crucial role of 
PI3K-Akt pathway in isosilybin B-mediated AR degradation. To further support this conclusion, we transfected 
LNCaP cells with 0.5 µg pCMV5-HA cAkt kinase mutant or pCMV5-HA (control) and treated with vehicle or 
isosilybin B. In HA-tagged control plasmid transfected cells, isosilybin B increased the Akt kinase activity and 
decreased the AR level (Figure 6b). However, in overexpressed kinase mutant Akt, we observed a 
comparatively much lesser decrease in AR level with isosilybin B, further suggesting an important role of Akt 
in isosilybin B-mediated AR decrease (Figure 6b). We also observed an increase in total Akt in the samples 
with overexpressed Akt kinase mutant compare to controls showing the efficiency of transfection (antibody 
used detects both wild-type and kinase mutant Akt; Figure 6b). 
 
Isosilybin B increases AR phosphorylation 
As we observed that isosilybin B causes Akt phosphorylation and increases its kinase activity as well, which is 
involved in AR degradation, and since Akt is known to phosphorylate and degrade AR (Lin et al., 2001, 2002), 
we next examined the effect of isosilybin B on phosphorylation status of AR at Ser-210/213 site in presence and 
absence of PI3K inhibitor. Indeed isosilybin B resulted in an increased phosphorylation of AR at Ser-210/213 
site, which was inhibited in the presence of PI3K inhibitor (Figure 6a). We next examined whether Akt 
physically interacts with AR by immunoprecipitating Akt followed by western blotting for AR, as well as 
immunoprecipitating AR followed by western blotting with anti-pAkt Ser-473 antibody. In both the cases, we 
observed an increased binding between the two molecules (Figure 6c). We also immunoblotted Akt and AR 
immunoprecipitates with their respective antibodies to support the validity of pull-down Akt and AR (data not 
shown). In addition, the specificity of the binding was confirmed by immunoprecipitation with normal 
immunoglobulin G (IgG), where no binding was observed (data not shown). These results suggest that 
isosilybin B treatment increases the binding between these two molecules that might result in AR 
phosphorylation. 
 
Isosilybin B increases Mdm2 phosphorylation and interaction with both Akt and AR 
Mdm2 (90 kDa) is a ring-finger protein whose E3-ligase activity plays a crucial role in ubiquitination and 
degradation of a number of proteins including AR (Zhou et al., 2001; Lin et al., 2002; Chen et al., 2005). 
Accordingly, we next examined the effect of isosilybin B on Mdm2 phosphorylation at Ser-166 site, which is 
associated with its activation and enhancement of ubiquitin ligase activity (Zhou et al., 2001; Lin et al., 2002; 
Paajarvi et al., 2005). Isosilybin B increased Mdm2 phosphorylation level at Ser-166 site in both LNCaP and 
22Rv1 cells (Figures 5b and c) without any change in total Mdm2 levels in 22Rv1 cells but in LNCaP cells we 
observed an increase in total Mdm2 levels after 48 and 72 h of treatment (Figures 5b and c). 
 
Earlier studies have also shown that Akt physically interacts with Mdm2 and phosphorylates it at Ser-166 site 
(Zhou et al., 2001; Lin et al., 2002). Therefore, we next examined whether isosilybin B-mediated Akt activation 
had any role in Mdm2 phosphorylation. The downregulation of Akt activation using LY294002 also resulted in 
an inhibition of isosilybin B-mediated phosphorylation of Mdm2 at Ser-166 (Figure 6a). Further, isosilybin B 
treatment significantly increased the binding between Mdm2 and Akt (Figure 6c). Similarly, we also observed 
an increased binding between Mdm2 and AR following isosilybin B treatment (Figure 6c). We also 
immunoblotted Mdm2 immunoprecipitates with its antibody to support the validity of pull-down Mdm2 (data 
not shown). In addition, the specificity of the binding was confirmed by immunoprecipitation with normal IgG, 
where no binding was observed (data not shown). Together, these results suggested that isosilybin B-mediated 
Akt 
 
activation leads to Mdm2 activation and its increased interaction with AR, which might lead to ubiquitination of 
AR followed by its degradation. 
 
Isosilybin B-triggered AR degradation is proteasome-mediated 
Protein ubiquitination provides the recognition signal for 26S proteasome leading to protein degradation 
(Hershko and Ciechanover, 1998). We next examined the role of ubiquitination and proteasomal activity in 
isosilybin B-mediated AR degradation. LNCaP cells were treated with 90 gM isosilybin B for 20 h and then 20 
gM 26S proteasomal inhibitor (MG132) was added. Cell lysates were prepared after 4 h of MG132 treatment 
and AR level was determined through western blotting. MG132 treatment largely restored the AR level 
decreased by isosilybin B (Figure 6d). Since inhibition of proteasomal activity by MG132 leads to an increase 
in polyubiquitinated form of AR, we stripped and reprobed the same blot with anti-ubiquitin antibody. There 
was an increase in the extent of ubiquitinated protein in the lanes treated with MG132 with or without isosilybin 
B treatment (Figure 6d). This result indirectly shows that MG132 treatment resulted in accumulation of 
ubiquitinated form of AR as proteasomal activity is inhibited; suggesting that isosilybin B-mediated AR 
degradation is largely proteasome dependent. 
 
Discussion 
Hormone-refractory relapse is an inevitable and lethal event for advanced PCA patients after hormone 
deprivation (Lee and Chang, 2003a; Chen et al., 2004). Notably, AR not only mediates the effect of androgen 
on tumor initiation but also plays major role in the relapse transition (Grossmann et al., 2001; Lee and Chang, 
2003a; Chen et al., 2004). This provides a strong rationale for searching new effective agents targeting the 
downregulation of AR to treat or prevent advanced PCA progression. Here, we have shown that isosilybin B 
treatment strongly decreases AR levels in human PCA LNCaP, 22Rv1 and LAPC4 cells. 
 
Androgen receptor is a nuclear receptor which binds to ARE and turns on its target genes regulating diverse cell 
functions such as cell growth and apoptosis (Grossmann et al., 2001). Isosilybin B treatment strongly inhibited 
the translocation of AR to the nucleus, which is, in turn, evident by a strong decrease in the expression levels of 
PSA. The present study also suggests that isosilybin B possesses strong antiandrogenic action as it inhibited 
R1881-induced AR expression/nuclear translocation, PSA expression and cell growth. The in vitro pre-
incubation of isosilybin B with R1881 also inhibited nuclear translocation of AR, which raises the possibility 
that isosilybin B can bind and sequester R1881. Alternatively, isosilybin B might also compete with R1881 for 
its binding with AR; at present it is not clear whether isosilybin B can interact directly with either wild-type or 
mutated AR. However, precedent exists for flavonolignan actions on other steroid hormone receptors. Silybin B 
exhibited selective partial agonist activity on estrogen-receptor-mediated reporter gene expression (EC25 = 4.4 
gM, 30% E2max induction) and the silymarin mixture exhibits ERR binding activity (Seidlova-Wuttke et al., 
2003; Pliskova et al., 2005). Another possibility is that isosilybin B may indirectly influence AR by targeting 
hsp90 chaperone, hsp90 cochaperones and/or other coregulators of AR, which play important role in proper 
folding, stability and nuclear translocation of AR (Lee and Chang, 2003b; Reddy et al., 2006). Indeed, these 
mechanisms and associated biological events require further investigation. 
 
Earlier studies have shown that downregulation of AR, using siRNA, antisense oligonucleotides or ribozymes, 
leads to an inhibition of PCA cell growth (Tong et al., 2003; Haag et al., 2005). In the present study, we 
observed a strong G1 arrest and growth inhibition by isosilybin B in the presence of serum or androgen in 
LNCaP cells. Consistent with these biological effects, recently we have reported that isosilybin B strongly 
inhibits cell growth by modulating cell cycle regulators and by activating caspases in both LNCaP and 22Rv1 
cells (Deep et al., 2007). There is a strong possibility that these growth inhibitory effects of isosilybin B might 
be due to antagonism of the androgen-AR signaling in both LNCaP and 22Rv1 cells. 
 
As mentioned earlier, AR activation is regulated by phosphorylation at multiple sites, which is regulated by 
many kinases. In the present study, we identified the role of Akt in isosilybin B-mediated AR degradation. It 




associated with loss of AR during the N-methylN-nitrosourea induced prostate carcinogenesis (Liao et al., 
2005). Sequence analysis of AR reveals two Akt consensus sequences (RXRXXS/T; Wen et al., 2000), thus Akt 
can interact directly with AR leading to its phosphorylation (Wen et al., 2000; Lin et al., 2001, 2002). We also 
observed that isosilybin B treatment results in the activation of Akt as evident by its increased phosphorylation 
and an increase in Akt kinase activity (Figure 6b) along with an increased binding between Akt and AR (Figure 
6c). These molecular alterations possibly were involved in an increased phosphorylation of AR together with its 
degradation. 
 
Other than acting directly, Akt can also influence AR level through other mechanisms; for example, Akt 
activation can activate mTOR, which has been reported to suppress AR level via post-transcriptional modifica-
tions (Cinar et al., 2005). Further, Akt activation can also decrease AR expression by reducing the levels of 
transcriptional factors, such as FOXO3a (Yang et al., 2005). Indeed, all these possibilities need to be examined 
in more details in future studies to further define the precise mechanisms underlying isosilybin B-mediated AR 
decrease via Akt activation. 
 
In the present study, we also observed that isosilybin B increases Akt-mediated phosphorylation of Mdm2.  
 
It has been shown earlier that AR ubiquitination is significantly impaired in Mdm2-deficient mouse embryonic 
fibroblasts (MEFs) compared with Mdm2- intact MEFs (Lin et al., 2002). Further, it seems that Mdm2 uses its 
RING-finger domain to interact with AR, and our binding assays clearly show that isosilybin B increases the 
interaction between AR and Mdm2 (Figure 6c), which might lead to ubiquitination of AR and its proteasomal-
mediated degradation (Figure 6d). Earlier studies have shown that in response to DNA damage, Mdm2 levels 
are increased in cells with wild- type p53 (Pan and Chen, 2003). Furthermore, the roles of MAP kinase and 
mTOR have also been suggested in the induction of Mdm2 levels (Paajarvi et al., 2005). Accordingly, more 
studies are needed to investigate these pathways, which might contribute to isosilybin B-mediated increased 
levels of Mdm2 phosphorylation and their relevance in the observed AR decrease by isosilybin B. 
 
In conclusion, the present study shows that isosilybin B strongly decreases AR levels in both androgen- 
dependent (LNCaP and LAPC4) and androgen-independent (22Rv1) PCA cells. Further, the present work for 
the first time suggested the role of activated Akt in AR degradation by a phytochemical, therefore, needs greater 
attention. Overall, the results from the present work provide a strong rationale for future investigation 
evaluating the efficacy of isosilybin B against PCA and associated mechanisms. 
 
Materials and methods 
Reagents 
Silybin A, silybin B, isosilybin A, isosilybin B were isolated (purity between 98 and 100%) from silymarin 
(Madaus AG, Cologne, Germany) as described (Kim et al., 2003). LNCaP, 22Rv1 and PWR-1E cells were from 
ATCC (Manassas, VA, USA). LAPC4 cells were kindly provided by Dr RE Reiter (UCLA, CA, USA). All cell 
culture materials were from Invitrogen (Gaithersberg, MD, USA); cFBS was from Hyclone (Logan, UT, USA). 
Antibodies for AR, Akt, Mdm2, normal mouse and rabbit IgG, and protein A/G agarose beads were from Santa 
Cruz Biotechnology (Santa Cruz, CA, USA). Akt kinase assay kit (nonradioactive) and antibodies for pAkt 
(Ser-473, Thr-308), Akt, pMdm2 Ser-166 and anti-rabbit peroxidase conjugated secondary antibody were from 
Cell Signaling (Beverly, MA, USA). PSA antibody was from Dako Corporation (Carpinteria, CA, USA). Anti-
body for pAR Ser-210/213 was from Imgenex (San Diego, CA, USA). Cycloheximide, propidium iodide, 4',6-
diamidino2-phenylindole (DAPI), and antibody for G-actin were from Sigma (St Louis, MO, USA). R1881 was 
from Perkin-Elmer (Wellesley, MA, USA). MG132 and LY294002 were from Biomol (Plymouth, PA, USA). 
Expression plasmids with dominant negative, kinase mutant Akt cDNA (pCM V5-HA-cAKT- KM) and 
pCMV5-HA (control) were kindly provided by Dr AD Cox, University of North Carolina at Chapel Hill. 
GeneJuice transfection reagent was from Novagen (Madison, WI, USA). Human PSA ELISA kit was from 
R&D Systems. ECL detection system and anti-mouse peroxidase conjugated secondary antibody were from GE 
Healthcare (Buckinghamshire, UK). 
 
Cell culture and treatments 
 LNCaP, 22Rv1 and PWR-1E cells were cultured as described earlier (Deep et al., 2007) and LAPC4 cells were 
cultured in Iscoves’s modified Dulbecco’s medium with 10% FBS, and 1 % penicillin-streptomycin (P-S). Cells 
were treated with different concentrations (10–90 gM) of isosilybin B, and/or isosilybin A, silybin A and silybin 
B (90 gM) in dimethyl sulfoxide (DMSO) for desired time. An equal amount of DMSO (vehicle) was present in 
each treatment including control, which did not exceed 0.1 % (v/v). LNCaP cells were also cultured in phenol 
red-free medium containing 10% cFBS and 1% P-S with or without synthetic androgen R1881 for 4 days, and 
isosilybin B was then added for further 24h. Media samples were separately collected, and cells were processed 
for whole-cell lysate, cytoplasmic and nuclear extracts, FACS analysis, or for cell viability assay as mentioned 
earlier (Muller et al., 1989; Zi et al., 1998; Zi and Agarwal, 1999). 
 
Western immunoblotting, and protein –protein binding and kinase assays 
For western blotting, 40–70 gg of protein per sample was denatured in 2 x SDS –polyacrylamide gel 
electrophoresis (PAGE) sample buffers and subjected to SDS–PAGE on 6, 8 or 12% polyacrylamide tris-
glycine gels followed by immunoblotting as described earlier (Muller et al., 1989; Zi et al., 1998). Protein–
protein binding studies were conducted as described earlier (Zi et al., 1998). Kinase activity assay for Akt was 
conducted as per vendor’s protocol with some modifications (Dhanalakshmi et al., 2005). 
 
Immunofluorescence staining and confocal imaging 
LNCaP cells were grown in 4-chamber slides in phenol red-free medium with 10% cFBS, and were pretreated 
with isosilybin B (90 gM) or DMSO for 120 min followed by synthetic androgen R1881 (1 nM) for another 150 
min. Cells were then fixed in 2% paraformaldehyde overnight at 4'C, permeabilized with 0.1 % Triton X-100 
for 15 min and then incubated with goat serum. Cells were washed with PBS containing 0.25% BSA and 
incubated with AR antibody for 1 h followed by 45 min incubation with fluorescein-tagged secondary antibody, 
and counterstained with DAPI for 5 min. Cell images were captured at x 400 magnification on a Nikon inverted 




LNCaP cells were transfected using GeneJuice as per vendor’s protocol. Briefly, cells were plated in 60 mm 
dishes and were transfected at about 50–60% confluency where 0.5 gg of pCMV5-HA cAkt KM (kinase 
mutant) or pCMV5-HA (control) was incubated with GeneJuice/serum free medium mixture for 15 min and 
then added dropwise to the cells. Cells were treated with DMSO or isosilybin B after 24h of transfection, and 
cell lysates prepared after 24h. 
 
ELISA assay for PSA 
ELISA assay for quantitative estimation of PSA in the media from LNCaP, 22Rv1 and LAPC4 cells was 
performed as per vendor’s protocol (R&D Systems, Minneapolis, MN, USA). 
 
Statistics 
Statistical analysis was performed using SigmaStat 2.03 software (Jandel Scientific, San Rafael, CA, USA). 
Data were analysed using Student’s t-test, and a statistically significant difference was considered to be at 
P<0.05. For all results autoradiograms/bands were scanned with Adobe Photoshop 6.0 (Adobe Systems Inc., 
San Jose, CA, USA) and the mean density of each band was analysed by the Scion Image program (National 
Institutes of Health (NIH), Bethesda, MD, USA). In each case, blots were subjected to multiple exposures on 
the film to ensure that the band density was in linear range. 
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